Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug.[7] It acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor.[8]
It was developed by Astellas Pharma.
In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive (both ITD and TKD[9]) relapsed or refractory acute myeloid leukemia (AML).[10]
In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.[11][5]
Gilteritinib was granted orphan drug status by the U.S. FDA, the European Commission (EC) and the Japan Ministry of Health, Labor and Welfare, for some AML patients.[12]
Gilteritinib was approved for medical use in Australia in March 2020.[13]
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 18.219.229.160